Enterprise Value

165.5M

Cash

384.9M

Avg Qtr Burn

-56.75M

Short % of Float

26.50%

Insider Ownership

17.06%

Institutional Own.

64.57%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
ALLO-647 (Anti-CD52 mAb) Details
Cancer, Diffuse large B cell lymphoma

Phase 3

Initiation

Cemacabtagene ansegedleucel, or cema-cel [ALLO-501A (CD19)] Details
Non-Hodgkin lymphoma, Cancer, Diffuse large B cell lymphoma

Phase 2

Data readout

ALLO-647 (Anti-CD52 mAb) Details
Cancer, Diffuse large B cell lymphoma

Phase 2

Update

ALLO-316 (CD70) Details
Renal cell carcinoma, Cancer, Solid tumor/s

Phase 1

Data readout

ALLO-715 (BCMA) Details
Cancer, Multiple myeloma

Phase 1

Update

ALLO-605 (BCMA) Details
Cancer, Multiple myeloma

Phase 1

Update